FDA and eight research organisations to collaborate in nanotechnology initiative
The US Food and Drug Administration (FDA) is to work with the Houston-based Alliance for NanoHealth (ANH) and its eight member institutions to help speed up development of safe and effective medical products in the emerging field of nanotechnology.
The US Food and Drug Administration (FDA) is to work with the Houston-based Alliance for NanoHealth (ANH) and its eight member institutions to help speed up development of safe and effective medical products in the emerging field of nanotechnology.
The FDA/ANH Nanotechnology Initiative will work to expand knowledge of how nanoparticles behave and affect biologic systems and develop tests and processes that might mitigate the risks associated with nanoengineered products.
"FDA's Nanotechnology Initiative with the Alliance for NanoHealth is an effort to engage resources and technical expertise in this rapidly advancing field and is a clear example of leveraging science and scientists to advance the public good," said Frank Torti, acting commissioner at the FDA. "Nanotechnology holds great promise for the advancement of novel medical products."
The eight academic institutions are: Baylor College of Medicine; the M D Anderson Cancer Centre at the University of Texas; Rice University; the University of Houston; Texas University's Health Science Centre at Houston; Texas A & M Health Science Centre; the University of Texas Medical Branch at Galveston; and the Methodist Hospital Research Institute.
"We see this agreement as an important step on the path to taking advantage of the enormous power of nanotechnology to improve the diagnosis and treatment of disease," said Larry Kaiser, president of the University of Texas Health Science Centre, speaking on behalf of the ANH and its eight members.